ALK Positive Non-Small Cell Lung Cancer- Pipeline Insight, 2025
Description
DelveInsight’s, “ALK Positive Non-Small Cell Lung Cancer- Pipeline Insight, 2025” report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in ALK Positive Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
ALK Positive Non-Small Cell Lung Cancer: Overview
Fusions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene were first identified as a likely molecular driver in patients with NSCLC. Anaplastic lymphoma kinase (ALK) gene rearrangements occur in a small portion of patients with non-small cell lung cancer (NSCLC). These gene rearrangements lead to constitutive activation of the ALK kinase and subsequent ALK driven tumor formation. Patients with tumors harboring such rearrangements are highly sensitive to ALK inhibitors such as crizotinib, ceritinib, and alectinib. About 90% of those diagnosed with ALK-positive cancer are diagnosed when the cancer has already spread to other parts of the body (known as metastatic cancer, or stage 4 cancer). Without any cancer treatment, half of patients with metastatic ALK cancer would die within less than 12 months, but with modern treatments that has that has increased more than six-fold, to over six years, in the last decade, and that median survival is continuing to increase as research discovers improved treatments and better medicines.
Lung cancer may not show symptoms until you’ve had it long enough for it to spread to other parts of the body. The symptoms associated with the lung cancer are coughing, worse chest pain with deep breathing or laughing, hoarseness, coughing up blood, weak or tired feeling, and wheezing.
Currently, ALK is diagnosed by genetic testing, known as molecular testing, of a sample. The National Comprehensive Cancer Center Network (NCCN) in the United States recommends that testing be performed via a broad, panel-based approach, typically by NGS. For patients who don’t have identifiable driver oncogenes by DNA NGS, consider RNA-based NGS to maximize detection of fusion events. To obtain a sample, it is necessary to undergo a biopsy, typically through a needle biopsy or a small surgical procedure.
Several organizations worked together to develop guidelines on who should be tested for an ALK mutation. The consensus was that all patients with advanced-stage adenocarcinoma should be tested for both ALK and EGFR mutations, regardless of gender, smoking history, other risk factors, and race. Patients diagnosed with lung cancer have to be proactive in requesting molecular testing for lung cancer mutations.
“ALK Positive Non-Small Cell Lung Cancer - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the ALK Positive Non-Small Cell Lung Cancer pipeline landscape is provided which includes the disease overview and ALK Positive Non-Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces, in depth ALK Positive Non-Small Cell Lung Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, ALK Positive Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the ALK Positive Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ALK Positive Non-Small Cell Lung Cancer Emerging Drugs
Further product details are provided in the report……..
ALK Positive Non-Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different ALK Positive Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 7+ products under different phases of clinical development like
ALK Positive Non-Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ALK Positive Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ALK Positive Non-Small Cell Lung Cancer drugs.
ALK Positive Non-Small Cell Lung Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
ALK Positive Non-Small Cell Lung Cancer: Overview
Fusions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene were first identified as a likely molecular driver in patients with NSCLC. Anaplastic lymphoma kinase (ALK) gene rearrangements occur in a small portion of patients with non-small cell lung cancer (NSCLC). These gene rearrangements lead to constitutive activation of the ALK kinase and subsequent ALK driven tumor formation. Patients with tumors harboring such rearrangements are highly sensitive to ALK inhibitors such as crizotinib, ceritinib, and alectinib. About 90% of those diagnosed with ALK-positive cancer are diagnosed when the cancer has already spread to other parts of the body (known as metastatic cancer, or stage 4 cancer). Without any cancer treatment, half of patients with metastatic ALK cancer would die within less than 12 months, but with modern treatments that has that has increased more than six-fold, to over six years, in the last decade, and that median survival is continuing to increase as research discovers improved treatments and better medicines.
Lung cancer may not show symptoms until you’ve had it long enough for it to spread to other parts of the body. The symptoms associated with the lung cancer are coughing, worse chest pain with deep breathing or laughing, hoarseness, coughing up blood, weak or tired feeling, and wheezing.
Currently, ALK is diagnosed by genetic testing, known as molecular testing, of a sample. The National Comprehensive Cancer Center Network (NCCN) in the United States recommends that testing be performed via a broad, panel-based approach, typically by NGS. For patients who don’t have identifiable driver oncogenes by DNA NGS, consider RNA-based NGS to maximize detection of fusion events. To obtain a sample, it is necessary to undergo a biopsy, typically through a needle biopsy or a small surgical procedure.
Several organizations worked together to develop guidelines on who should be tested for an ALK mutation. The consensus was that all patients with advanced-stage adenocarcinoma should be tested for both ALK and EGFR mutations, regardless of gender, smoking history, other risk factors, and race. Patients diagnosed with lung cancer have to be proactive in requesting molecular testing for lung cancer mutations.
“ALK Positive Non-Small Cell Lung Cancer - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the ALK Positive Non-Small Cell Lung Cancer pipeline landscape is provided which includes the disease overview and ALK Positive Non-Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces, in depth ALK Positive Non-Small Cell Lung Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, ALK Positive Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence ALK Positive Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve ALK Positive Non-Small Cell Lung Cancer.
This segment of the ALK Positive Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ALK Positive Non-Small Cell Lung Cancer Emerging Drugs
- SY-3505: Shouyao Holdings
- APG-2449: Ascentage Pharma
Further product details are provided in the report……..
ALK Positive Non-Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different ALK Positive Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in ALK Positive Non-Small Cell Lung Cancer
Phases
DelveInsight’s report covers around 7+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
ALK Positive Non-Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ALK Positive Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ALK Positive Non-Small Cell Lung Cancer drugs.
ALK Positive Non-Small Cell Lung Cancer Report Insights
- ALK Positive Non-Small Cell Lung Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing ALK Positive Non-Small Cell Lung Cancer drugs?
- How many ALK Positive Non-Small Cell Lung Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ALK Positive Non-Small Cell Lung Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ALK Positive Non-Small Cell Lung Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for ALK Positive Non-Small Cell Lung Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Nuvalent
- Shouyao Holdings
- Xuanzhu Biopharmaceutical
- Fochon Pharmaceutical
- NVL-655
- SY-3505
- XZP-3621
- SAF 189
Table of Contents
60 Pages
- Introduction
- Executive Summary
- ALK Positive Non-Small Cell Lung Cancer : Overview
- Introduction
- Function
- Symptoms
- Diagnosis
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Assessment by Product Type
- Assessment by Stage and Product Type
- ALK Positive Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- SY-3505: Shouyao Holdings
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Product Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- APG-2449: Ascentage Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- ALK Positive Non-Small Cell Lung Cancer - Collaborations Assessment- Licensing / Partnering / Funding
- ALK Positive Non-Small Cell Lung Cancer - Unmet Needs
- ALK Positive Non-Small Cell Lung Cancer - Market Drivers and Barriers
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
